Grand Rounds

A Focus on Special Populations in Relapsed Multiple Myeloma

Mary Steinbach,(1) DNP, APRN, Kathleen Colson,(2) RN, BSN, BS, and Beth Faiman,(3) PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN

From (1)Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; (2)Dana-Farber Cancer Institute, Boston, Massachusetts; (3)Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail: faimanb@ccf.org


J Adv Pract Oncol 2022;13(Suppl 4):23–30 | https://doi.org/10.6004/jadpro.2022.13.5.12 | © 2022 Harborside™


  

ABSTRACT

The overall care of patients with multiple myeloma can present similar challenges. However, disparities in health care require that providers consider each individual’s unique circumstances. Disparities based on ethnic/racial group, religion, socioeconomic status, age, sexual orientation or gender identity, or other characteristics can lead to patients receiving less than optimal care and therefore poorer outcomes. Patients who have received more than two lines of therapy can acquire new genetic changes, accelerated cadence of relapse, and suffer from disease sequelae such as pain from prior or ongoing skeletal fractures, recurrent infections, and progressive decline in organ function. Numerous treatment options remain for patients in their first three relapses. Well-designed clinical trials with newer drugs are preferred. Clinicians should discuss clinical trial options and availability with all patients in spite of disparities that may exist. Patients facing disparities are at risk for suboptimal care and should be closely monitored and provided appropriate resources. Continued attention to disease and organ surveillance are critical throughout the course of the disease.

Multiple Myeloma and Plasma Cell Disorders: Update on Diagnosis, Prognosis, Treatment, and Supportive Care
Introduction
A Focus on Newly Diagnosed Multiple Myeloma
A Focus on Relapsed Multiple Myeloma
A Focus on Special Populations in Relapsed Multiple Myeloma
A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
A Focus on Waldenström Macroglobulinemia and AL Amyloidosis




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.